The company's platform analyzes patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge Genomics aims to dramatically improve patient outcomes and lower the cost of pharmaceutical development by identifying breakthrough drugs. They are focused on tackling ALS, Parkinson's Disease, and Alzheimer's Disease and offer growth opportunities for employees within the company.